DANIEL B SOLAND
CIK 1318485 · CHIEF OPERATING OFFICER · last filed 2025-06-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.17M
Companies
5
Total Filings
53
Lifetime Open-Market Net
$169.8K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ACAD | Director | 44,041 | $26.01 | $1.15M | $234.9K | 14 | 2025-06-02 |
| DBVT | Director | 2,000 | $13.50 | $27.0K | $24.3K | 2 | 2023-08-03 |
| Aceragen, Inc. (IDRA) Delisted | CHIEF OPERATING OFFICER | 4,638 | $7.22 | $33.5K | $98.5K | 7 | 2022-07-07 |
| KalVista Pharmaceuticals, Inc. (KALV) Delisted | Director | 10,000 | $27.00 | $270.0K | $118.7K | 5 | 2021-10-01 |
| VIROPHARMA INC (VPHM) Delisted | VP, Chief Operating Officer | 148,188 | — | — | -$306.6K | 24 | 2014-01-10 |
Recent Filings · Page 2 of 6
53 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-06-24 | ACAD | Grant (A) | — | $0 | EDGAR |
| 2021-06-21 | Aceragen, Inc. (IDRA) Delisted | Buy (P) | +50,000 | $59.5K | EDGAR |
| 2021-06-11 | DBVT | Buy (P) | — | $0 | EDGAR |
| 2021-03-05 | Aceragen, Inc. (IDRA) Delisted | Buy (P) | +10,000 | $39.0K | EDGAR |
| 2021-01-05 | Aceragen, Inc. (IDRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-10-02 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-10-02 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-25 | ACAD | Grant (A) | — | $0 | EDGAR |
| 2019-09-30 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Buy (P) | +10,000 | $118.7K | EDGAR |
| 2019-06-28 | ACAD | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.